Track topics on Twitter Track topics that are important to you
Zurich-Schlieren, Switzerland, June 29, 2010. Molecular Partners AG, the global leader in the development of DARPins as unique next generation protein therapeutics, announced today the appointment of Dr Göran Ando as independent non-executive member of the board of directors.
Dr Ando brings considerable experience to the board of Molecular Partners, having been CEO of Celltech Group, plc. Prior to this, he was Executive Vice President and President R&D for Pharmacia, now Pfizer Inc., where he was also responsible for manufacturing, IT, business development and Mergers & Acquisitions. He has also held positions as R&D Director of Glaxo Group, UK, and was a member of the Glaxo Group Executive Committee. He currently serves as Vice Chairman of the Board of Directors of Novo Nordisk A/S and as Senior Advisor to Essex Woodlands Health Ventures. Dr Ando is a Physician and Specialist in General Medicine and is a Founding Fellow of the American College of Rheumatology in the US.
Jörn Aldag, Chairman of the Board of Directors at Molecular Partners said: “I am delighted to welcome Göran to the board of Molecular Partners. He brings with him a wealth of scientific and general management experience at a time where Molecular Partners is transitioning from a pre-clinical to a clinical stage product development company. He will prove invaluable to Molecular Partners in supporting many of our portfolio decisions as the Company continues to expand.”
Dr Göran Ando added: “This is an exciting time to be joining Molecular Partners. Having secured deals with major pharmaceutical partners, one of the largest fundraisings in Europe last year, and with their first products entering the clinic, the Company is in an excellent position, and I look forward to being part of its continued success.”
- ends -
For further details please contact:
Dr. Christian Zahnd, CEO
Tel: +41 (0) 44 755 77 00
Tel: +44 (0) 20 7866 7864
Notes to editors:
About Molecular Partners ( www.molecularpartners.com ):
Molecular Partners is a privately held biotech company focusing on the commercialization of a novel class of biological drugs known as DARPins. The company is committed to create medicines for diseases with unmet medical need and to dramatically improve existing therapies. DARPins combine the high specificity, selectivity and safety of monoclonal antibodies with many advantages of small molecules, including high stability and low-cost production.
Molecular Partners has established a strong DARPin pipeline which is well differentiated from standard therapeutic approaches. The lead molecule, MP0112, is a VEGF-A antagonist which is in clinical trials for the treatment of ocular diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Next to MP0112, Molecular Partners is focusing on DARPin drugs in inflammation, oncology and other disease areas. The internal pipeline is expanded by partnered programs with leading pharmaceutical companies. Molecular Partners has established collaborations with F. Hoffmann-la Roche, Centocor Research & Development Inc. and Bayer Schering Pharma. The company is backed by a strong syndicate of investors and holds a strong patent estate covering all DARPin applications.Molecular Partners Dr. Christian Zahnd, CEO Tel: +41 (0) 44 755 77 00 firstname.lastname@example.org Media relations Tony Stephenson Tel: +44 (0) 20 7866 7864 email@example.com NEXT ARTICLE
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...